Connect with us

Health

EMA approves 12 medicines including combined COVID-19 and influenza vaccine

SHARE:

Published

1 week ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

At its February 2026 meeting, EMA’s human medicines committee (CHMP) recommended 12 medicines for approval, covering vaccines, innovative treatments and biosimilars, and issued two negative opinions.

A major highlight was mCombriax, the first combined mRNA vaccine to protect adults aged 50 and over against both COVID-19 and seasonal influenza. With hundreds of millions of COVID-19 cases reported in Europe and tens of millions of flu cases annually in the EEA, the dual vaccine aims to reduce the burden of seasonal respiratory infections.

"The CHMP's positive opinion represents an important milestone for respiratory virus vaccination and for Moderna, with the introduction of the world's first flu plus COVID combination vaccine," said Stéphane Bancel, Chief Executive Officer of Moderna. "

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending